UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 126

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

126
TI
How I treat leukemia during pregnancy.
AU
Milojkovic D, Apperley JF
SO
Blood. 2014 Feb;123(7):974-84. Epub 2013 Nov 22.
 
Leukemia in pregnancy remains a challenging therapeutic prospect. The prevalence is low at∼1 in 10 000 pregnancies, and as a result data are limited to small retrospective series and case reports, rendering evidence-based recommendations for management strategies difficult. The management of the leukemias in pregnancy requires close collaboration with obstetric and neonatology colleagues as both the maternal and fetal outcomes must be taken into consideration. The decision to introduce or delay chemotherapy must be balanced against the impact on maternal and fetal survival and morbidity. Invariably, acute leukemia diagnosed in the first trimester necessitates intensive chemotherapy that is likely to induce fetal malformations. As delaying treatment in this situation is usually inappropriate, counseling with regard to termination of pregnancy is often essential. For chronic disease and acute leukemia diagnosed after the second trimester, therapeutic termination of the pregnancy is not inevitable and often, standard management approaches similar to those in nongravid patients can be used. Here, the management of the acute and chronic leukemias will be addressed.
AD
Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
PMID